Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2020.

"Adaptive's launch of T-Detect COVID marks a pivotal moment in the diagnostic testing paradigm. We have now proven that it is possible to read how T cells detect disease in the blood and we are on a fast path to develop this product for many other indications," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "As we move into 2021, we are poised to execute on several key catalysts across all business areas that will accelerate our vision to power the age of immune medicine."

Recent Highlights

  • Revenues of $30.2 million for the fourth quarter and $98.4 million for the full year of 2020, representing a 25% increase and 16% increase, respectively, over the corresponding periods in 2019.
  • Clinical sequencing volume increased 41% to 4,539 clinical tests delivered in the fourth quarter of 2020, compared to the fourth quarter 2019 and ended the year with 15,216 clinical tests delivered, up 50% versus 2019.
  • Launched T-Detect™ COVID, first clinical T-cell based test for patients to confirm recent or prior COVID-19 infection. In final review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).
  • Extended collaboration agreement with Labcorp to enable broader access to our growing portfolio of immune-driven clinical diagnostic and research products.
  • Submitted a 510(k) application to the FDA for the use of clonoSEQ in blood for B-cell acute lymphoblastic leukemia (ALL) patients.

Fourth Quarter 2020 Financial Results

Revenue was $30.2 million for the quarter ended December 31, 2020, representing a 25% increase from the fourth quarter in the prior year. Sequencing revenue was $12.7 million for the quarter, representing an 8% decrease from the fourth quarter in the prior year. Development revenue was $17.5 million for the quarter, representing a 69% increase from the fourth quarter in the prior year.

Operating expenses were $74.4 million for the fourth quarter of 2020, compared to $48.4 million in the fourth quarter of the prior year, representing an increase of 54%.

Net loss was $44.6 million for the fourth quarter of 2020, compared to $20.6 million for the same period in 2019.

Adjusted EBITDA (non-GAAP) was a loss of $34.6 million for the fourth quarter of 2020, compared to a loss of $18.7 million for the fourth quarter of the prior year.

Full Year 2020 Financial Results

Revenue was $98.4 million for the year ended December 31, 2020, representing a 16% increase from the prior year. Sequencing revenue was $41.4 million in 2020, representing a 5% decrease from 2019. Development revenue was $56.9 million in 2020, representing a 37% increase from the prior year.

Operating expenses for 2020 were $251.2 million, compared to $163.5 million for 2019, representing an increase of 54%.

Net loss was $146.2 million in 2020, compared to $68.6 million in 2019.

Adjusted EBITDA (non-GAAP) was a loss of $119.6 million for 2020, compared to a loss of $57.5 million in the prior year.

Cash, cash equivalents and marketable securities was $806.8 million as of December 31, 2020.

2021 Financial Guidance

Management will provide the 2021 outlook during the conference call scheduled to discuss the 2020 financial results.

Webcast and Conference Call Information

Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2020 financial results after market close on Wednesday, February 24, 2021 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward-Looking Statements

This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Use of Non-GAAP Financial Measure

To supplement our balance sheets and statements of operations, which are prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss adjusted for interest and other income, net, income tax (expense) benefit, depreciation and amortization and share-based compensation expenses. We have provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation, or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:

  • all expenditures or future requirements for capital expenditures or contractual commitments;
  • changes in our working capital needs;
  • income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;
  • the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;
  • the non-cash component of employee compensation expense; and
  • the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.

In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

ADAPTIVE MEDIABeth Keshishian917-912-7195media@adaptivebiotech.com

ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations201-396-1687Carrie Mendivil, Gilmartin Groupinvestors@adaptivebiotech.com

Adaptive BiotechnologiesStatements of Operations(in thousands, except share and per share amounts)(unaudited)

    Three Months Ended December 31,     Year Ended December 31,  
    2020     2019     2020     2019  
Revenue                                
Sequencing revenue   $ 12,709     $ 13,888     $ 41,439     $ 43,519  
Development revenue     17,476       10,321       56,943       41,552  
Total revenue     30,185       24,209       98,382       85,071  
Operating expenses                                
Cost of revenue     6,222       5,951       22,530       22,274  
Research and development     35,831       21,189       116,072       70,705  
Sales and marketing     18,545       12,640       61,358       38,453  
General and administrative     13,398       8,189       49,536       30,332  
Amortization of intangible assets     428       428       1,703       1,698  
Total operating expenses     74,424       48,397       251,199       163,462  
Loss from operations     (44,239 )     (24,188 )     (152,817 )     (78,391 )
Interest and other income, net     785       3,577       6,590       9,785  
Income tax expense     (1,116 )                  
Net loss     (44,570 )     (20,611 )     (146,227 )     (68,606 )
Fair value adjustment to Series E-1 convertible preferred stock  options                       (964 )
Net loss attributable to common shareholders   $ (44,570 )   $ (20,611 )   $ (146,227 )   $ (69,570 )
Net loss per share attributable to common shareholders, basic  and diluted   $ (0.33 )   $ (0.17 )   $ (1.11 )   $ (1.01 )
Weighted-average shares used in computing net loss per share  attributable to common shareholders, basic and diluted     136,954,148       124,397,150       131,216,468       69,165,315  
                                 

Adaptive BiotechnologiesBalance Sheets(in thousands, except share and per share amounts)(unaudited)

    December 31,  
    2020     2019  
Assets                
Current assets                
Cash and cash equivalents   $ 123,436     $ 96,576  
Short-term marketable securities (amortized cost of $564,036 and $479,791, respectively)     564,833       480,290  
Accounts receivable, net     10,047       12,676  
Inventory     14,063       9,069  
Prepaid expenses and other current assets     14,535       14,079  
Total current assets     726,914       612,690  
Long-term assets                
Property and equipment, net     39,692       60,355  
Operating lease right-of-use assets     99,350        
Long-term marketable securities (amortized cost of $118,429 and $105,263, respectively)     118,525       105,435  
Restricted cash     2,138       2,138  
Intangible assets, net     10,225       11,928  
Goodwill     118,972       118,972  
Other assets     598       784  
Total assets   $ 1,116,414     $ 912,302  
Liabilities and shareholders' equity                
Current liabilities                
Accounts payable   $ 3,237     $ 4,453  
Accrued liabilities     13,162       4,371  
Accrued compensation and benefits     11,950       8,124  
Current portion of deferred rent           371  
Current portion of operating lease liabilities     3,529        
Current portion of deferred revenue     73,319       60,994  
Total current liabilities     105,197       78,313  
Long-term liabilities                
Deferred rent liability, less current portion           6,918  
Operating lease liabilities, less current portion     104,333        
Financing obligation           36,607  
Deferred revenue, less current portion     163,618       219,332  
Other long-term liabilities           93  
Total liabilities     373,148       341,263  
Commitments and contingencies                
Shareholders' equity                
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019            
Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2020 and 2019; 137,646,896 and 125,238,142 shares issued and outstanding at December 31, 2020 and 2019, respectively     14       12  
Additional paid-in capital     1,253,971       935,834  
Accumulated other comprehensive gain     893       671  
Accumulated deficit     (511,612 )     (365,478 )
Total shareholders' equity     743,266       571,039  
Total liabilities and shareholders' equity   $ 1,116,414     $ 912,302  
                 

Adjusted EBITDAThe following table sets forth a reconciliation between our Adjusted EBITDA and our net loss, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands, unaudited):

    Three Months Ended December 31,     Year Ended December 31,  
    2020     2019     2020     2019  
Net loss   $ (44,570 )   $ (20,611 )   $ (146,227 )   $ (68,606 )
Interest and other income, net     (785 )     (3,577 )     (6,590 )     (9,785 )
Income tax expense     1,116                    
Depreciation and amortization expense     2,352       2,075       8,472       7,791  
Share-based compensation expense     7,243       3,411       24,761       13,124  
Adjusted EBITDA   $ (34,644 )   $ (18,702 )   $ (119,584 )   $ (57,476 )